GlobalRPh RX List - carboplatin IV
- Product / population
- Carboplatin intravenous injection; oncology regimen and target exposure must be confirmed separately. No patient-specific calculation is supplied.
- Renal measure
- CrCl for renal caution; GFR in mL/min in the separate Calvert relationship
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Selected sections only; not a complete prescribing monograph or independent clinician approval.
A hosted label mirror is not independent corroboration of its underlying label. Official confirmation remains pending unless a separate official card is shown.
Renal dosing, restrictions and evidence limits
The mirror associates CrCl below 60 mL/min with increased severe myelosuppression. Below 15 mL/min, data are insufficient for a treatment recommendation. Initial-course guidance must not replace later adjustment to marrow tolerance.
It describes the Calvert relationship: total dose in mg = target AUC x (GFR in mL/min + 25), not mg/m2. The underlying studies used measured Cr-EDTA clearance. This is not authorization to substitute any reported eGFR or select an AUC.
The retrieved BSA-based renal table loses its range separators. Those rows are withheld rather than repaired by assumption; no new clearance-band dosing table is published.